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To the Editor: One-third of patients with ST-segment elevation
myocardial infarction, usually those presenting late, show ongoing
left ventricular (LV) remodeling and poor clinical outcome despite
primary percutaneous coronary intervention (PCI) (1). Cardiac
transfer of bone marrow-derived stem cells has been investigated as
an adjunctive therapy to promote the repair of infarcted myocar-
dium (2–5). Therefore, we designed a randomized study to test the
safety and efficacy of intracoronary injection of autologous bone
marrow-derived mononuclear cells (BMNCs) in patients with
large acute anterior myocardial infarction and late presentation
who were treated with successful primary PCI.
The study population consisted of 27 consecutive patients (age
59  12 years; 81% males) with the first ST-segment elevation
acute anterior myocardial infarction due to occlusion of the
proximal left anterior descending artery (LAD) who had under-
gone successful primary stented PCI. Patients were eligible if they
had primary PCI from 4 to 24 h after symptoms onset and showed
a reduced LV ejection fraction 50% with at least 3 akinetic
segments in the LAD territory. The study protocol was approved
by the Medical Ethical Committees from all involved institutions,
and informed consent was obtained from all patients.
Eligible patients were randomly assigned in a 2:1 ratio either to
intracoronary BMNCs injection (n  17) or standard medical
therapy (n  10). In the BMNCs group, aspiration of BMNCs
was performed 4 to 11 days after PCI. After isolation, mononu-
clear BMNCs concentrate was infused in the LAD using a
stop-flow technique through an over-the-wire balloon catheter (2).
At baseline and 4-month follow-up, LV ejection fraction and
volumes were assessed by echocardiography with the biplane
Simpson methods, infarct size with single-photon emission com-
puted tomography combining perfusion by technetium-99m ses-
tamibi and glucose uptake by F-18-fluorodeoxyglucose. Coronary
angiography was repeated at 4 months. All statistical analyses were
conducted according to the intention-to-treat principle. Two-
sided paired and unpaired Student t test or Fisher exact test was
used as appropriate. For all tests, p  0.05 was considered
significant.
Baseline characteristics, including infarct size (maximum crea-
tine kinase 2,995 1,975 U/l vs. 2,751 789 U/l, p ns), degree
of LV dysfunction (ejection fraction 38  7% vs. 39  4%, p 
NS) and proportion of patients with Thrombolysis In Myocardial
Infarction flow grade 3 after PCI (77% vs. 80%, p  NS) were
comparable between groups. The median time from pain onset to
PCI was 5 h (interquartile range [IQR] 5 to 11) in both groups
(p  NS). The median time from PCI to BMNCs intracoronary
injection was 9 days (range 4 to 11 days). On average, 171 48 ml
of bone marrow blood was harvested and processed to a final
volume of 27  7 ml. The median number of injected BMNCs
and CD34 cells was 26.4 108 (IQR 19.6 108 to 33.0 108)
and 1.3  106 (IQR 1.1  106 to 1.4  106), respectively. The
viability of BMNCs ranged from 94% to 99%. Intracoronary
transfer of BMNCs was successful in all patients, and no serious
periprocedural complications or increase in cardiac markers were
observed.
At 4-month follow-up (Table 1), infarct size decreased, and LV
ejection fraction improved to a similar extent in both groups
whereas LV volumes did not changed significantly. In the BMNCs
group, insignificantly more dysfunctional segments showed im-
provement in contractile function as compared with the control
group.
Regarding the safety, 2 patients developed serious complications
during or after bone marrow harvest. One patient had a ventricular
septal rupture before the injection of BMNCs, underwent
emergency surgery, and died 3 months later as the result of
severe heart failure. The other patient suffered a stent throm-
bosis with reinfarction immediately after we harvested the
BMNCs. He had a complicated PCI followed by coronary
artery bypass grafting and died 2 weeks later from sepsis and
acute respiratory distress syndrome. Another patient had diag-
nosed biliary carcinoma 6 weeks after BMNCs’ transfer and
died 2 months later. One BMNC patient suffered from reinfarc-
tion due to LAD occlusion distally to the implanted stent 9
months after randomization.
One patient in each group was hospitalized for worsening heart
failure. The rate of revascularization was similar in both groups
(24% in the BMNCs group and 40% in the control group; p 
NS). At 12-month follow-up, LV ejection fraction (46  7% vs.
49  13%; p  NS) improved to a similar extent. No patient
developed malignant arrhythmias. The original intention was to
enroll a total of 40 patients in the BMNCs group and 20 patients
in the Control group. After enrollment of the initial 27 patients,
the trial was terminated prematurely because of the unexpected
occurrence of serious complications in the BMNCs group and no
incremental functional effects of BMNCs as compared with
control patients.
This randomized study showed that, in patients with large acute
anterior myocardial infarction and late presentation, intracoronary
infusion of BMNCs in the infarct-related coronary artery at a
median of 9 days after primary PCI does neither increase recovery
of LV ejection fraction nor reduce LV volumes and infarct size at
4 months, as compared with control subjects. Four randomized
trials (2–5) have been conducted so far to investigate the functional
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effects of BMNCs intracoronary injection in patients with smaller
acute myocardial infarction with controversial results. Only 1 trial
(4) reported enhanced and sustained recovery of LV ejection
fraction in the BMNCs group as compared with control patients.
In the present study, we enrolled a homogenous population of
patients with extensive anterior myocardial infarction with an
ejection fraction 6.7% to 11.3% lower than in all previous trials.
Nevertheless, corroborating data from previous trials (3,5), did
not observe any improvement in ejection fraction by BMNCs
over primary PCI alone. Low regenerative potential (6) and low
engraftment in the heart after intracoronary injection (7) may
be the major explanations for lack of functional effects of
BMNCs.
The present study has several limitations. The number of
enrolled patients was small, and the study was terminated prema-
turely. Hence, the potential treatment effect could be missed. Yet,
inclusion of more patients would have not been likely to change the
results. In contrast to previous studies, we included patients with
poor LV function, late revascularization, and late BMNCs injec-
tions. It may be possible that this subset of patients does not
benefit from the transplantation of BMNCs. Hence, our results are
not necessarily in contradiction with positive results of larger trials
(4). It should be pointed out that adverse events observed in the
study do not seem to be directly related to the BMNCs procedure.
No complications were observed during the injection of BMNCs.
Given the laborious nature of BMNC harvest and intracoronary
transfer, small, if any, functional effects, and lack of prognostic
data, the routine use of BMNCs after acute myocardial infarction
cannot be recommended at the present time.
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LV Systolic Global and Regional Function, LV Volumes, and Infarct Size at Baseline and 4-Month Follow-Up
Table 1 LV Systolic Global and Regional Function, LV Volumes, and Infarct Size at Baseline and 4-Month Follow-Up
BMNCs Group (n  14)* Control Group (n  10)
p Value Follow-Up
BMNCs vs. Control GroupValue Change From Baseline Value Change From Baseline
LV end-diastolic volume (ml) NS
Baseline 163 30 162 30
4 months 172 34 15.5% 174 29 17.4%
LV end-systolic volume (ml) NS
Baseline 98 25 98 23
4 months 95 28 23.1% 96 28 22.0%
LV ejection fraction (%) NS
Baseline 39 6 39 4
4 months 45 9† 115.4% 47 7† 120.5%
Akinetic and severely hypokinetic segments
in the LAD perfusion territory
NS
Baseline 5.9 1.6 5.8 1.8
4 months 3.5 2.6‡ 240.7% 3.8 2.4‡ 234.5%
Infarct size at SPECT (%) NS
Baseline 41.4 18.3 47.5 20.8
Follow-up 30.5 16.1‡ 226.3% 35.3 17.2‡ 225.7%
*The 4-month functional follow-up data are reported in 14 patients in the BMNCs group who survived the first 4 months after randomization. †p  0.05, ‡p  0.01 baseline versus follow-up.
BMNC  bone marrow-derived mononuclear cell; LAD  left anterior descending; LV  left ventricular; NS  not significant; SPECT  single-photon emission computed tomography.
2374 Correspondence JACC Vol. 49, No. 24, 2007
June 19, 2007:2373–7
